MarketInOut Stock Screener Log In | Sign Up

MediWound Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
MediWound Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization171.71 mln
Float9.62 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.92
Likely reliable

Relative Strength

93 / 100
Top performer

Debt / Equity

0.27
Very low leverage

Pre-Tax Margin

-169%
Severely loss-making

ROE

-52.83
Deeply negative

Business Description

Founded in 2000 and based in Yavne, Israel, MediWound develops and sells biological treatments that help heal damaged tissue without surgery, operating across the United States, Europe, and other markets. Its main product, NexoBrid, is used in burn centers to remove dead tissue from serious burn wounds. The company is also working on EscharEx, an enzyme-based therapy for chronic and difficult-to-heal wounds, as well as a topical treatment for a common form of skin cancer.

Key Fundamentals

EPS-2.17
ROE-52.83
RPS0.96
ROIC-74.58
ROA-25.25
Interest Cover-28.35
EBITDA, mln-17.03
EV / EBITDA-7.98
EV / EBIT-7.18
Revenue, mln11.86
EV / Revenue11.45

Quote Details

Last 13.30
Change -0.56 (-4.04%)
Open 13.94
Volume 110,075
Turnover 1,463,998
Average Volume 101,218

Financial Ratios

Pre-Tax Profit Margin-169
Leverage Ratio2.02
Current Ratio2.32
Price / Book4.55
Price / Tangible Book4.55
Debt / Equity0.27
Price / Sales12.63

Financial Strength

Altman Z-Score-2.27
Piotroski F-Score 3 / 9
Beneish M-Score-2.92
Short Ratio24.32
Short % of Float15.48

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.83% 94 / 100   
1 Month -2.21% 47 / 100   
2 Months -7.96% 35 / 100   
6 Months -20.02% 27 / 100   
1 Year -26.4% 28 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog